Federal Trade Commission v. Vyera Pharmaceuticals, LLC

District Court, S.D. New York·Decided June 1, 2021·No. 1:20-cv-00706·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------- X : FEDERAL TRADE COMMISSION, STATE OF NEW : 20cv00706 (DLC) YORK, STATE OF CALIFORNIA, STATE OF : OHIO, COMMONWEALTH OF PENNSYLVANIA, : OPINION AND ORDER STATE OF ILLINOIS, STATE OF NORTH : CAROLINA, and COMMONWEALTH OF : VIRGINIA, : : Plaintiffs, : : -v- : : VYERA PHARMACEUTICALS, LLC, AND : PHOENIXUS AG, MARTIN SHKRELI, : individually, as an owner and former : director of Phoenixus AG and a former : executive of Vyera Pharmaceuticals, : LLC, and KEVIN MULLEADY, individually, : as an owner and former director of : Phoenixus AG and a former executive of : Vyera Pharmaceuticals, LLC, : : Defendants. : : -------------------------------------- X

APPEARANCES:

For plaintiff Federal Trade Commission: Markus H. Meier Bradley S. Albert Armine Black Daniel W. Butrymowicz Neal J. Perlman J. Maren Schmidt James H. Weingarten Lauren Peay Leah Hubinger Federal Trade Commission 600 Pennsylvania Avenue, NW Washington, DC 20580 (202) 326-3748 For plaintiff State of New York: Letitia James Christopher D’Ange Elinor R. Hoffman Saami Zain Amy McFarlane Jeremy Kasha Bryan Bloom Office of the New York Attorney General Antitrust Bureau 28 Liberty Street, 20th Floor New York, NY 10005 (212) 416-8262

For plaintiff State of California: Michael D. Battaglia Office of the Attorney General of California 455 Golden Gate Avenue, Suite 11000 San Francisco, CA 94102 (415) 510-3769

For plaintiff State of Ohio: Beth Finnerty Elizebeth M. Maag Office of the Ohio Attorney General 150 E. Gay Street, 22nd Floor Columbus, OH 43215 (614) 466-4328

For plaintiff Commonwealth of Pennsylvania: Joseph Betsko Pennsylvania Office of Attorney General Strawberry Square, 14th Floor Harrisburg, PA 17120

For plaintiff State of Illinois: Richard S. Schultz Office of the Attorney General of Illinois 100 W. Randolph Street, 11th Floor Chicago, IL 60601 (312) 814-3000

For plaintiff State of North Carolina: K.D. Sturgis Jessica V. Sutton North Carolina Dept. of Justice Consumer Protection Division 114 West Edenton Street Raleigh, NC 27603 (919) 716-6000

For plaintiff Commonwealth of Virginia: Sarah Oxenham Allen Tyler T. Henry Office of the Attorney General of Virginia 202 North Ninth Street Richmond, VA 23219

For defendant Martin Shkreli: Christopher H. Casey, Esq. A.J. Rudowitz, Esq. Jeffrey Pollack Sarah O’Laughlin Kulik Duane Morris LLP 30 South 17th Street Philadelphia, PA 19103-4196 (215) 979-1155

For defendant Kevin Mulleady: Albert Shemmy Mishaan Kenneth R. David Nicholas Rendino Kasowitz Benson Torres LLP 1633 Broadway New York, NY 10023 (212) 506-1700

DENISE COTE, District Judge:

In a letter of May 17, 2021, the plaintiffs seek sanctions under Rule 37(e) against defendant Martin Shkreli (“Shkreli”) on the ground that Shkreli spoliated relevant messages on two mobile devices. Shkreli and Vyera responded in letters of May 21. For the reasons that follow, Shkreli’s proposed sanctions are adopted, and Vyera is directed to submit a letter of clarification regarding the completeness of its discovery production. Background

The events underlying this antitrust action are described in an Opinion of August 18, 2020, which is incorporated by reference. See Fed. Trade Comm'n v. Vyera Pharms., LLC, 479 F.Supp.3d 31 (S.D.N.Y. 2020). Briefly, Shkreli and defendant Kevin Mulleady (“Mulleady”) launched Vyera Pharmaceuticals, LLC (“Vyera”) in 2014. In August 2015, Vyera acquired the U.S. rights to the branded drug Daraprim, which is used to treat toxoplasmosis. The active pharmaceutical ingredient of Daraprim is pyrimethamine. The plaintiffs’ amended complaint alleges that Vyera entered into several anti-competitive agreements with companies, including exclusive supply agreements. One such agreement was with RL Fine Chem (“RL Fine”), which Vyera entered

in November 2017 after learning that RL Fine was preparing to seek FDA approval for the manufacture of pyrimethamine. Shkreli received document hold notices in the fall of 2015. The plaintiffs seek sanctions based on spoliation of “messages” from two different mobile devices: (1) Shkreli’s company-issued iPhone (“Shkreli Phone”) and (2) a contraband cell phone Shkreli used while in prison (“Prison Phone”). I. Company-Issued Phone Vyera issued Shkreli the Shkreli Phone, and Shkreli kept the Shkreli Phone after he left the company at the end of 2015.

Shkreli’s brother and sister took possession of the Shkreli Phone when Shkreli was incarcerated in September 2017.1 In April 2020, Shkreli’s counsel sent the Shkreli Phone to an IT vendor to be forensically imaged. In a letter of June 16, 2020, Shkreli’s counsel notified the plaintiffs that the Shkreli Phone “was subject to a factory reset in or around 2016-2017.” A factory reset wipes all communications stored on the cell phone. Neither Shkreli nor Vyera produced any messages from the Shkreli Phone during discovery. Vyera has repeatedly represented that it automatically backs up to iCloud messages sent from company-issued cell phones. No party has suggested that a factory reset of the Shkreli Phone had any impact on the

iCloud storage of the phone’s data. In its response to the plaintiffs’ motion for sanctions, counsel for Shkreli states: “although Vyera backed up its employees’ phones, no messages sent to or from Mr. Shkreli’s corporate phone have been produced by any party, suggesting that no relevant messages exist on that phone.”

1 Shkreli was convicted in the Eastern District of New York and sentenced on March 9, 2018 principally to a term of imprisonment of seven years. II. The Contraband Phone Vyera executive Akeel Mithani has testified that he communicated with Shkreli about business development from the

end of 2018 through February 2019, while Shkreli was incarcerated. Shkreli sometimes used the WhatsApp application on the Prison Phone to communicate with Mithani. Mithani testified that Shkreli -- who remains incarcerated -- still reaches out to him with business development suggestions. Mulleady also produced in discovery two text messages that he received from Shkreli in October 2017, while Shkreli was incarcerated. Vyera has informed the plaintiffs that it does not possess -- and likely cannot access -- WhatsApp messages exchanged between Mithani and Shkreli while Shkreli was in prison. Shkreli was deposed on January 28, 2021. When he was asked whether he had a cell phone in prison, he invoked his

Fifth Amendment rights and declined to answer. Discussion A party’s “obligation to preserve evidence arises when the party has notice that the evidence is relevant to litigation or when a party should have known that the evidence may be relevant to future litigation.” In re Terrorist Bombings of U.S. Embassies in E. Afr., 552 F.3d 93, 148 (2d Cir. 2008) (citation omitted). “Spoliation is the destruction or significant alteration of evidence, or failure to preserve property for another's use as evidence in pending or reasonably foreseeable litigation.” Id. (citation omitted). Rule 37(e) governs the failure to preserve electronically

stored information (“ESI”). Under Rule 37(e), a court may sanction a party for failure to preserve ESI “[i]f electronically stored information that should have been preserved in the anticipation or conduct of litigation is lost because a party failed to take reasonable steps to preserve it, and it cannot be restored or replaced through additional discovery.” Fed. R. Civ. P. 37(e). Rule 37(e) provides two sanctions for spoliation.

Free access — add to your briefcase to read the full text and ask questions with AI

Federal Trade Commission v. Vyera Pharmaceuticals, LLC, (S.D.N.Y. 2021).

Federal Trade Commission v. Vyera Pharmaceuticals, LLC (Federal Trade Commission v. Vyera Pharmaceuticals, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Klipsch Group, Inc. v. ePRO E-Commerce Ltd.
880 F.3d 620 (Second Circuit, 2018)
Cat3, LLC v. Black Lineage, Inc.
164 F. Supp. 3d 488 (S.D. New York, 2016)
United States v. Odeh
552 F.3d 93 (Second Circuit, 2008)